Clinical Trial Update: Neoadjuvant Imiquimod Immunotherapy for Oral Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase neoadjuvant immunotherapy trial evaluating imiquimod for oral squamous cell carcinoma has completed, with results posted in January 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Squamous Cell Carcinoma

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Oral Squamous Cell Carcinoma | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2025-01-28